NeOnc Technologies NTHI 深 沪
等待开盘 11-10 09:30:00 美东时间
3.74
+0.250
+7.16%
华盛通- 最 高3.90
- 今 开3.85
- 成交量 32.03万股
- 最 低 3.52
- 昨 收 3.49
- 总市值 1.08亿
- 52周最高 11.3765
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 2.501
- 委 比 -33.33%
- 总股本 2885.06万
- 历史最高 25.00
- 量 比 2.74
- 振 幅 10.89%
- 历史最低 2.501
- 每 手 1
- 风险率 2.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeOnc Technologies CEO Amir Heshmatpour Buys 70K Shares At Average Price Of $3.29/Share
The transactions took place on November 5 and 6, with Heshmatpour purchasing 30,000 shares at a weighted average price of approximately $3.17 on the first day and another 40,000 shares at approximately $3.39 on the second. His reported beneficial ownership increased to approximately 7.77 million sha...
11-09 21:39
NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues
NeOnc Technologies Holdings CEO Amir Heshmatpour purchased 70,000 shares of the company's stock for approximately $230,510 on November 5 and 6, reflecting ongoing confidence in the company. NeOnc is developing NEO100, an intranasal treatment for recurrent IDH1-mutant high-grade glioma, and NEO212, a therapy for central nervous system cancers. NEO100 Phase 2a results met the primary endpoint with a six-month progression-free survival rate of 48.9%...
11-09 13:32
NeOnc Technologies Q3 EPS $(0.28) Misses $(0.24) Estimate
NeOnc Technologies (NASDAQ:NTHI) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 37.78 percent increase over losses of $(0.45) per share from the same period last year.
11-05 22:19
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
NeOnc Technologies Holdings, Inc. announced that data from its intranasal NEO100 and oral NEO212 programs will be presented at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) on November 13, 2026. NEO100 is a perillyl alcohol administered intranasally, while NEO212 is an oral conjugate of temozolomide and NEO100, both under investigation for CNS cancers. The company aims to advance new therapies for brain cancer ...
11-02 13:00
NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage
NeOnc Technologies Holdings (NASDAQ:NTHI) is advancing a pivotal clinical trial targeting approximately 500 patients across 30 hospitals in three countries to address difficult-to-treat brain cancers. The trial focuses on NEO100, an investigational treatment using intranasal administration to bypass the blood-brain barrier. Encouraging early results include significant radiographic remission in 24% of patients. Additionally, NEO212, another drug ...
10-30 13:10
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
NeOnc Technologies Holdings (NASDAQ:NTHI) has seen its stock price break above $3, supported by strong trading volume and improving technical indicators, signaling a potential reversal. The company has also reported increased short interest, which could amplify volatility. NeOnc recently announced a Memorandum of Understanding with Abu Dhabi's Department of Health, advancing its brain tumor therapies, and shared positive clinical observations fro...
10-23 17:01
NeOnc Technologies Signs MoU With Abu Dhabi's Health Department Over Development Research And Clinical Capability In Oncology, Centrla Nervous System Therapeutics
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it has signed a Memorandum of Understanding (MoU) with the Department of Health – Abu Dhabi (DoH...
10-21 20:02
NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development
NeOnc Technologies Holdings (NASDAQ:NTHI) has strengthened its board with the appointment of Ali Alabedin, adding over three decades of international banking and leadership experience. The company is advancing its NEO drug platform, targeting challenges in delivering therapies across the blood-brain barrier. NEO212 has completed Phase 1 and is moving toward Phase 2, with UAE regulatory support. Recent milestones include positive results from the ...
10-14 14:18
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity is enormous. Management seems pretty sure the rest of us will eventually recognize its brilliance. The...
10-08 23:32
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
<p>2026年，多家公司在癌症治疗领域取得显著进展，为患者带来新希望。NeOnc Technologies Holdings的NEO100治疗复发性脑癌患者，实现中位总生存期26.09个月；Revolution Medicines的Rasonque获FDA批准，显著延长胰腺癌患者生存期；Moderna与Merck合作的个性化mRNA免疫疗法在III期试验中取得积极结果；Johnson & Johnson的双靶点免疫疗法在多发性骨髓瘤治疗中表现出色；Genmab与AbbVie的Epcoritamab在淋巴瘤治疗中也取得突破。这些进展展示了在现有治疗不足领域改善患者预后的潜力。</p>
10-07 13:43
